Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
  • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
  • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
  • G16B40/20—Supervised data analysis
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
  • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
  • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
  • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/158—Expression markers

Definitions

• the present invention relates to methods for predicting multiple myeloma treatment response.
• MM Multiple myeloma
• MMC malignant plasma cells
• Decitabine (5-aza-2'-deoxycytidine) or 5-azacytidine are both clinically used DNMT inhibitors for the treatment of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) (Hollenbach, 2010).
• MDS myelodysplastic syndrome
• AML acute myelogenous leukemia
• MM clinical trials are ongoing with DNMTi as monotherapy or combined with lenalidomide or dexamethasone (Maes, 2013).
• Histone deacetylases represent also molecular targets for the treatment of different cancers including MM (Feng, 2008; Khan, 2004; Lavelle, 2001; Mitsiades, 2004; Mitsiades, 2003; Catley, 2003; Kaiser, 2006; Neri, 2012; Neri, 2008; Minami, 2013; Hideshima, 2013).
• Romidepsin and Vorinostat SAHA have been approved by the Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (Zhang, 2009) and several HDACi are evaluated in clinical trials in MM (Maes, 2013; Neri, 2012).
• HDACi and DNMTi treatment can induce MAGE-A3 in MM, an attractive target for immunotherapy, and facilitate killing by MAGE -A3 specific cytotoxic T lymphocytes (Moreno-Bost, 2011).
• Matthews et al investigated the potential of combining HDACi with a BH3-only mimetic (ABT-737), recombinant human TNF-related apoptosis-inducing ligand (rfiTRAIL) or 5-azacitidine, in vivo, using the Vk*MYC transgenic MM mouse model (Matthews, 2013).
• HDACi and DNMTi demonstrated a significant reduction of tumor load in vivo and prolonged survival of mice without toxicity (Matthews, 2013).
• HDACi and DNMTi combination was well tolerated (Bots, 2009) and suggested promising activity in MDS, AML (Bots, 2009; Fandy, 2009; Zhang, 2009) and refractory advanced non-small cell lung cancer (Juergens, 2011).
• MMCs Multiple Myeloma Cells
• HDACi/DNMTi score or "HADMS” that makes it possible identification of patients whose MMCs will be targeted by a combination treatment consisting of at least one DNA methyltransferase inhibitor (DNMTi) with at least one histone deacetylase inhibitor (HDACi).
• DNMTi DNA methyltransferase inhibitor
• HDACi histone deacetylase inhibitor
• the present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one DNA methyltransferase inhibitor (DNMTi) with at least one histone deacetylase inhibitor (HDACi).
• DNMTi DNA methyltransferase inhibitor
• HDACi histone deacetylase inhibitor
• HDACi histone deacetylase inhibitor
• DNMTi DNA methyltransferase inhibitors
• HMCLs human multiple myeloma cell lines
• HADM score histone acetylation/DNA methylation score
• HADMS histone acetylation/DNA methylation score
• the inventors reported a new gene expression-based score to predict the myeloma cell sensitivity to a combination treatment consisting of at least one DNA methyltransferase inhibitor (DNMTi) with at least one histone deacetylase inhibitor (HDACi).
• HADM score allows identification of high-risk patients associated with MMC's higher sensitivity to a combination treatment consisting of at least one DNA methyltransferase inhibitor (DNMTi) with at least one histone deacetylase inhibitor (HDACi), which is useful in identifying patients who could benefit from combination of epigenetic therapy.
• a patient denotes a mammal.
• a patient refers to any patient (preferably human) afflicted with multiple myeloma.
• multiple myeloma refers to multiple myeloma such as revised in the World Health Organisation Classification C90.
• histone deacetylase inhibitor has its general meaning in the art and refers to a multiple myeloma treatment.
• histone deacetylase inhibitor or “HDACi” refers to histone deacetylase inhibitor that can be grouped in four classes: hydroxamates (panobinostat (LBH-589), trichostatin-A (TSA), vorinostat (SAHA), belinostat (PXD101), NVP-LAQ824 and givinostat (ITF2357)), cyclic peptide (romidepsin (depsipeptide)), aliphatic acids (valproic acid (VPA) and sodium phenylbutyrate) and benzamides (MS-275, MGCD0103) (10).
• hydroxamates panobinostat (LBH-589), trichostatin-A (TSA), vorinostat (SAHA), belinostat (PXD101), NVP-LAQ824 and givin
• HDACi are characterized as class I-specific HDACs inhibitors (MGCD0103, romidepsin and MS-275) or as pan-HDAC inhibitors, denoting activity against both classes I and II HDACs (TSA, panobinostat, vorinostat and belinostat) (10).
• DNA methyltransferase inhibitors or “DNMTi” has its general meaning in the art and refers to a multiple myeloma treatment.
• DNA methyltransferase inhibitors or “DNMTi” refers to DNA methyltransferase inhibitor that can be sub-divided into nucleoside analogue (5-Azacytidine (azacytidine), 5-Aza-2'-deoxycytidine (decitabine, 5- Aza-CdR), zebularine, 5-Fluoro-2'-deoxycytidine (5-F-CdR), 5,6-Dihydro-5-azacytidine (DHAC)) and non-nucleoside analogue families (Hydralazine, Procainamide, Procaine, EGCG ((-)-epigallocatechin-3-gallate), Psammaplin A, MG98, RG108) (8).
• nucleoside analogue 5-Azacytidine
• biological sample refers to multiple myeloma cells, bone marrow or medullary cell.
• Table A Set of predictive genes.
• the present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitor (DNMTi) comprising:
• HADMS ⁇ ⁇ ⁇ ⁇
• the expression levels of at least 42 genes from Table A are determined wherein said genes are: EPAS1, ATP1B1, TJP2, RAB13, IFI27, PLSCR1, CYP1B1, SLC2A3, IFIT1, SCHIP1, PDZK1, DDR1, HLA-DRA, SERPINB9, SP110, SSX4, Clorf38, FN1, MXRA7, CLIC5, HIST1H2AE, MGC14376, HLA-DRB1 , SLC2A14, USP18, DKFZp434C0328, CDC14B, DDX58, PARP9, TMPRSS3, COTL1, PARP14, KIAA1671, GDAP1, LOC129607, SLC27A1, FLJ13611, KSR, HIST1H2BD, 240979_at EST, BIRC4BP and RSAD2.
• the expression levels of 42, 43, 44, 45, 46, 47, 48, 49, 50 are: EPAS1,
• Every combinations of genes comprises a minimal set of 42 genes consisting of: EPAS1, ATP1B1, TJP2, RAB13, IFI27, PLSCR1, CYP1B1, SLC2A3, IFIT1, SCHIP1, PDZK1, DDR1, HLA-DRA, SERPINB9, SP110, SSX4, Clorf38, FN1, MXRA7, CLIC5, HIST1H2AE, MGC14376, HLA-DRB 1 , SLC2A14
• the expression level as determined is a relative expression level. More preferably, the determination comprises contacting the biological sample with selective reagents such as probes, primers or ligands, and thereby detecting the presence, or measuring the amount, of polypeptide or nucleic acids of interest originally in the biological sample. Contacting may be performed in any suitable device, such as a plate, microtiter dish, test tube, well, glass, column, and so forth. In specific embodiments, the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array or a specific ligand array.
• the substrate may be a solid or semi-solid substrate such as any suitable support comprising glass, plastic, nylon, paper, metal, polymers and the like.
• the substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc.
• the contacting may be made under any condition suitable for a detectable complex, such as a nucleic acid hybrid or an antibody-antigen complex, to be formed between the reagent and the nucleic acids or polypeptides of the biological sample.
• the expression level may be determined by determining the quantity of mR A.
• nucleic acid contained in the biological sample is first extracted according to standard methods, for example using lytic enzymes or chemical solutions or extracted by nucleic-acid-binding resins following the manufacturer's instructions.
• the extracted mRNA is then detected by hybridization (e. g., Northern blot analysis) and/or amplification (e.g., RT- PCR).
• hybridization e. g., Northern blot analysis
• amplification e.g., RT- PCR
• RT-PCR e.g., RT- PCR
• quantitative or semi-quantitative RT-PCR is preferred. Real-time quantitative or semi-quantitative RT-PCR is particularly advantageous.
• LCR ligase chain reaction
• TMA transcription- mediated amplification
• SDA strand displacement amplification
• NASBA nucleic acid sequence based amplification
• Nucleic acids having at least 10 nucleotides and exhibiting sequence complementarity or homology to the mRNA of interest herein find utility as hybridization probes or amplification primers. It is understood that such nucleic acids need not be identical, but are typically at least about 80% identical to the homologous region of comparable size, more preferably 85% identical and even more preferably 90-95% identical. In certain embodiments, it will be advantageous to use nucleic acids in combination with appropriate means, such as a detectable label, for detecting hybridization. A wide variety of appropriate indicators are known in the art including, fluorescent, radioactive, enzymatic or other ligands (e. g. avidin/biotin).
• Probes typically comprise single-stranded nucleic acids of between 10 to 1000 nucleotides in length, for instance of between 10 and 800, more preferably of between 15 and 700, typically of between 20 and 500.
• Primers typically are shorter single- stranded nucleic acids, of between 10 to 25 nucleotides in length, designed to perfectly or almost perfectly match a nucleic acid of interest, to be amplified.
• the probes and primers are "specific" to the nucleic acids they hybridize to, i.e. they preferably hybridize under high stringency hybridization conditions (corresponding to the highest melting temperature Tm, e.g., 50 % formamide, 5x or 6x SCC.
• SCC is a 0.15 M NaCl, 0.015 M Na-citrate).
• the nucleic acid primers or probes used in the above amplification and detection method may be assembled as a kit.
• a kit includes consensus primers and molecular probes.
• a preferred kit also includes the components necessary to determine if amplification has occurred.
• the kit may also include, for example, PCR buffers and enzymes; positive control sequences, reaction control primers; and instructions for amplifying and detecting the specific sequences.
• the methods of the invention comprise the steps of providing total R As extracted from a biological samples and subjecting the R As to amplification and hybridization to specific probes, more particularly by means of a quantitative or semi-quantitative RT-PCR.
• the expression level is determined by DNA chip analysis.
• DNA chip or nucleic acid microarray consists of different nucleic acid probes that are chemically attached to a substrate, which can be a microchip, a glass slide or a microsphere-sized bead.
• a microchip may be constituted of polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, or nitrocellulose.
• Probes comprise nucleic acids such as cDNAs or oligonucleotides that may be about 10 to about 60 base pairs.
• a biological sample from a test patient optionally first subjected to a reverse transcription, is labelled and contacted with the microarray in hybridization conditions, leading to the formation of complexes between target nucleic acids that are complementary to probe sequences attached to the microarray surface.
• the labelled hybridized complexes are then detected and can be quantified or semi- quantified. Labelling may be achieved by various methods, e.g. by using radioactive or fluorescent labelling.
• Many variants of the microarray hybridization technology are available to the man skilled in the art (see e.g. the review by Hoheisel, Nature Reviews, Genetics, 2006, 7:200-210)
• the invention further provides a DNA chip comprising a solid support which carries nucleic acids that are specific to the genes listed in Table A.
• Predetermined reference values ELRi or HADMS R used for comparison may consist of "cut-off values.
• each reference (“cut-off) value ELRi for each gene may be determined by carrying out a method comprising the steps of:
• step e providing, for each sample provided at step a), information relating to the actual clinical outcome for the corresponding cancer patient (i.e. the duration of the disease-free survival (DFS), or the event free survival (EFS) or the overall survival (OS) or both);
• information relating to the actual clinical outcome for the corresponding cancer patient i.e. the duration of the disease-free survival (DFS), or the event free survival (EFS) or the overall survival (OS) or both
• DFS disease-free survival
• EFS event free survival
• OS overall survival
• the expression level of a gene Gi has been assessed for 100 samples of 100 patients.
• the 100 samples are ranked according to the expression level of gene Gi.
• Sample 1 has the highest expression level and sample 100 has the lowest expression level.
• a first grouping provides two subsets: on one side sample Nr 1 and on the other side the 99 other samples.
• the next grouping provides on one side samples 1 and 2 and on the other side the 98 remaining samples etc., until the last grouping: on one side samples 1 to 99 and on the other side sample Nr 100.
• Kaplan Meier curves are prepared for each of the 99 groups of two subsets. Also for each of the 99 groups, the p value between both subsets was calculated.
• the reference value ELRi is then selected such as the discrimination based on the criterion of the minimum p value is the strongest.
• the expression level corresponding to the boundary between both subsets for which the p value is minimum is considered as the reference value. It should be noted that according to the experiments made by the inventors, the reference value ELRi is not necessarily the median value of expression levels.
• the reference value HADMS R is the median value of HADMS.
• the reference value ELRi for the gene Gi is described in table A (right column).
• the regression ⁇ coefficient reference values may be easily determined by the skilled man in the art for each gene Gi using a Cox model.
• the Cox model is based on a modeling approach to the analysis of survival data. The purpose of the model is to simultaneously explore the effects of several variables on survival.
• the Cox model is a well-recognised statistical technique for analysing survival data. When it is used to analyse the survival of patients in a clinical trial, the model allows us to isolate the effects of treatment from the effects of other variables.
• the logrank test cannot be used to explore (and adjust for) the effects of several variables, such as age and disease duration, known to affect survival. Adjustment for variables that are known to affect survival may improve the precision with which we can estimate the treatment effect.
• the regression method introduced by Cox is used to investigate several variables at a time.
• the procedure models or regresses the survival times (or more specifically, the so-called hazard function) on the explanatory variables.
• the hazard function is the probability that an individual will experience an event (for example, death) within a small time interval, given that the individual has survived up to the beginning of the interval. It can therefore be interpreted as the risk of dying at time t.
• the quantity hO (t) is the baseline or underlying hazard function and corresponds to the probability of dying (or reaching an event) when all the explanatory variables are zero.
• the regression coefficient ⁇ gives the proportional change that can be expected in the hazard, related to changes in the explanatory variables.
• the coefficient ⁇ is estimated by a statistical method called maximum likelihood.
• the regression ⁇ coefficient reference values are described in Table A.
• the reference value HADMS R is -21 .57 for determining whether a patient suffering from multiple myeloma will respond to the combination treatment of the invention and for predicting the survival time of patient suffering from multiple myeloma.
• the invention also relates to a kit for performing the methods as above described, wherein said kit comprises means for measuring the expression level of the genes listed in Table A.
• the kit may include a primer, a set of primers, a probe, a set of probes as above described.
• the probe or set of probes are labelled as above described.
• the kit may also contain other suitably packaged reagents and materials needed for the particular detection protocol, including solid-phase matrices, if applicable, and standards.
• the score may be generated by a computer program.
• the method of the invention allows to define a subgroup of patients who will be responsive ("responder") or not ("non responder") to the treatment with the combination treatment consisting of at least one histone deacetylase inhibitor with at least one DNA methyltransferase inhibitor.
• a further object of the invention relates to a method for the treatment of multiple myeloma in a patient in need thereof.
• the term “treating” or “treatment”, as used herein means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
• the method comprises the following steps:
• a further object of the invention relates to a combination treatment consisting of at least one histone deacetylase inhibitor with at least one DNA methyltransferase inhibitor for use in the treatment of multiple myeloma in a patient in need thereof, wherein the patient was being classified as responder by the method as above described.
• a further object of the invention relates to a combination treatment consisting of trichostatin-A (TSA) or vorinostat (SAHA) with decitabine (5-aza-2'-deoxycytidine) or 5- azacytidine for use in the treatment of multiple myeloma in a patient in need thereof, wherein the patient was being classified as responder by the method as above described.
• TSA trichostatin-A
• SAHA vorinostat
• decitabine 5-aza-2'-deoxycytidine
• 5- azacytidine for use in the treatment of multiple myeloma in a patient in need thereof, wherein the patient was being classified as responder by the method as above described.
• FIGURES are a diagrammatic representation of FIGURES.
• Figure 1 Clustergram of the signals of the 96 genes used to build HADMS score in myeloma cells of 206 previously untreated patients.
• HADMS score are displayed from low (deep blue) to high (deep red) expression.
• Figure 3 Prognostic value of HADMS score in multiple myeloma.
• HADMS score -21.57 splitting patients in high risk (23.7%) and low risk (76.3%) groups.
• the prognostic value of HADMS score was validated using an independent cohort of 345 patients from UAMS treated with TT2 therapy (UAMS- TT2 cohort). The parameters to compute the HADMS score of patients of UAMS- TT2 cohort and the proportions delineating the 2 prognostic groups were those defined with HM cohort.
• the HADMS score could also predict for event free survival (EFS) in the HM and UAMS-TT2 cohorts.
• Figure 4 HADMS score predicts for sensitivity of primary myeloma cells of patients to HDACi/DNMTi combined treatment.
• FIG. 6 HADMS in MMCs of patients using UAMS-TT2 cohort.
• the HADMS score was computed for MMCs of patients belonging to the 8 groups of the UAMS molecular classification of multiple myeloma, using UAMS-TT2 cohort.
• PR proliferation
• LB low bone disease
• MS MMSET
• HY hyperdiploid
• CD1 Cyclin Dl
• CD2 Cyclin D2
• MF MAF
• MY myeloid.
• HMCLs Human Myeloma Cell Lines
• HMCLs (XG-5, XG-6, XG-7, XG-20 and LP1) were treated with 0.5 ⁇ /L Decitabine (Sigma, St Louis, MO) for 7 days in RPMI 1640, 10% fetal bovine serum supplemented with IL-6 for IL-6 dependent HMCLs. During the last 24 hours, 0.33 ⁇ /L TSA (Sigma) was added as described by Heller et al (Heller, 2008). Whole genome gene expression profiling was assayed with Affymetrix U133 2.0 plus microarrays (Affymetrix).
• HADMS Score was constructed as the sum of the Cox model beta coefficients of each of the Decitabine/TSA combination deregulated genes with a prognostic value, weighted by ⁇ 1 according to the patient MMC signal above or below the probeset maxstat value (Kassambara, 2012; Moreaux, 2012; Moreaux, 2013).
• Significantly enriched pathways were identified using Reactome functional interaction map.
• Gene set enrichment analysis was carried out by computing overlaps with canonical pathways and gene ontology gene sets obtained from the Broad Institute (Subramanian, 2005). Results
• Cell viability (%)
• Table 1 Cell viability of HMCLs treated with 0.5 ⁇ decitabine for 7 days and 0.33 ⁇ during the last 24 hours. Data are the mean percentages + SD of viable cells evaluated by trypan blue exclusion (3 experiments).
• CD44 MX1,HLA-DQA1.HLA-DPA1,GBP2,GBP1,HLA-DRA,IF1TM1,HLA-DRB1,1FITM2,0AS1,0AS2,HLA-
• EGF receptor signaling pathway 0.0089 82 0004 4.44e-03 PIK3CD,CBLB,AREG,TGFA,STAT4,STAT1
• HADMS score was significantly associated with high-risk myeloma in the 2 independent patients' cohorts, HM and UAMS- TT2 ( Figure 3A).
• the HADMS score could also predict for event free survival (EFS).
• EFS event free survival
• the prognostic value of the HADMS score was compared to usual prognostic factors ( ⁇ 2 ⁇ , ISS, t(4;14) and dell7p) and published GEP-based risk scores: UAMS-HRS (Shaughnessy, 2007), IFM score (Decaux, 2008), GPI (Hose, 201 1), RS score (Reme, 2013), DM score (Moreaux, 2012) and HA score (Moreaux, 2013).
• UAMS-HRS Shaaughnessy, 2007
• IFM score Decaux, 2008
• GPI Hose, 201 1
• RS score Reme, 2013
• DM score Me, 2013
• DM score Me, 2013
• HA score Mereme, 2013
• HADMS score and ⁇ 2 ⁇ remained independent in the HM cohort.
• Pronostic Proportional P-value Proportional P-value variable hazard ratio hazard ratio
• Table 4 Cox univariate and multivariate analysis of OS in HM and TT2 patients' cohorts. The prognostic factors were tested as single variable or multi variables using Cox- model. P-values and the hazard ratios (HR) are shown.
• NS Not significant at a 5% threshold
• GPI gene expression based proliferation index
• ISS International Staging System
• HRS high-risk score
• IFM Intergroupe Francophone du Myelome
• DM score DNA Methylation score, HA score, Histone Acetylation score, Serum concentration of ⁇ 2 ⁇ and albumin are not available for UAMS TT2 patients.
• NA Not available.
• HADMS score is predictive of myeloma cell sensitivity to DNMTi and HDACi combination.
• MMC of patients with low HADMS score value are characterized by mature BMPC gene signature whereas patients with high HADMS score have a proliferating plasmablastic gene signature.
• MMCs of patients with a high HADMS score exhibited a significant enrichment in genes associated with proliferating plasmablastic progenitors (gene sets: MOREAUX MULTIPLE MYELOMA BY TACI DN, WHITFIELD CELL CYCLE S, P ⁇ 0.01, Tables 10 and 11), IFN regulated genes (gene sets: REACTOME INTERFERON ALPHA BETA SIGNALING, RADAEVA RESPONSE TO IFNAl UP and DER IFN BETA RESPONSE UP, P ⁇ 0.01, Table 12, 13 and 14) and transcription (gene set: REACTOME TRANSCRIPTION, P ⁇ 0.0001, Table 15).
• PrePB, P 0.05
• MB memory B
• PLA2G7 PLA2G7 0.12095429003238678 0.6436146 Yes
• NUDCD2 NUDCD2 -0.08143609762191772 -0.6673385 Yes NASP NASP -0.09491787105798721 -0.6665999 Yes
• Table 10 Genes set enrichment analysis revealed a significant overrepresentation of the MOREAUX MULTIPLE MYELOMA BY TACI DN set in high HADMS score patients compared to low HADMS score patients (P ⁇ 0.0001).
• ISG15 ISG15 -0.39782193303108215 4.5454444E-4 Yes
• Table 15 Genes set enrichment analysis revealed a significant overrepresentation of the REACTOME TRANSCRIPTION set in high HADMS score patients compared to low HADMS score patients (PO.0001).
• HADMS score allows identification of high-risk patients associated with MMC's higher sensitivity to HDACi/DNMTi combination in vitro. Since HDACi/DNMTi combination was well tolerated (Bots, 2009), shown promising activity in cancers including haemato logical malignancies (Bots, 2009; Fandy, 2009; Zhang, 2009; Juergens, 2011) and have potential therapeutic value in MM (Matthews, 2013), the HADMS score could enable the identification of MM patients who could benefit from this treatment.
• the 96 genes, building HADMS score include 42 genes associated with a bad prognosis and 54 associated with a good prognosis (Figure 1). Among these genes, some of them could highlight pathways involved in MM biology and sensitivity to DNMTi/HDACi combination. Since a significant enrichment in genes associated with proliferation was identified in MMC of patients with high HADMS score value, the higher sensitivity of high HADMS score patients to DNMTi/HDACi combination could be explained by the fact that incorporation of DNMTi into DNA is restricted to cell cycling cells (Hollenbach, 2010).
• HDACi have been shown to induce Gl cell cycle arrest through dephosphorylation of retinoblastoma protein and increase expression of p53 and p21 (Lavelle, 2001; Mitsiades, 2003; Neri, 2012).
• methylation-specific PCR several studies have identified hypermethylation of tumor suppressor genes including cyclin dependent kinases inhibitors (CDKI, pl5 and pl6) and pl4 (Braggio, 2010; Takada, 2005; Mateos, 2002).
• CDKI cyclin dependent kinases inhibitors
• pl4 cyclin dependent kinases inhibitors
• the inventors reported DNMTi/HDACi treatment induced p21 and p57 CDKI expression in MMC (Table A) and their expression is associated with a good prognosis in MM patients (Table A).
• Cdcl4b has been proposed to play multiple functions during the cell cycle (Mocciaro, 2010).
• Cdcl4 protein phosphatase is essential for the inactivation of mitotic CDK and mitotic exit (Mocciaro, 2010; Wei, 2011).
• Cells of Cdcl4b-deficient mice displayed proliferative defects and increased senescence both in vitro and in vivo (Wei, 2011). More recently, it was reported that the lack of Cdcl4b results in a significant increased transcription of cell cycle specific genes including A and B-type cyclins.
• EGF negative regulator ERRFIl also known as Mig-6
• ERRFIl deletion in mice has been reported to activate EGFR and sustain MAPK signaling, resulting in tumor development (Zhang, 2007; Anastasi, 2007; Ferby, 2006).
• ERRFIl deletion, mutation or downregulation have been frequently identified in glioblastoma, lung and breast cancers (Anastasi, 2005; Ichimura, 2008; Ying, 2010).
• ERRFI1 overexpression was shown to decrease proliferation, the binding of EGFR with STX8 and drive internalized EGFR to endosomes for degradation.
• ERRFIl depletion resulted in increased tumor invasion (Ying, 2010).
• Ying, 2010 a recent study demonstrated that ERRFIl expression is upregulated during the senescence process (Xie, 2013).
• the inventors have previously demonstrated that the EGF/EGF-receptor family is involved in the biology of MM (Mahtouk, 2006; Mahtouk, 2005; Mahtouk, 2004) acting as myeloma cell growth factors.
• DNMTi/HDACi combination could be useful to induce the expression of major tumor suppressor genes in MMC.
• HADMS score patients are characterized by an overexpression of genes related to transcription including histone cluster genes (Table 15). Core histone proteins must be synthetized rapidly during the brief S-phase when a cell is dividing (Harris, 1991). As a result, the histone mRNAs are highly cell-cycle regulated, increasing 35-fold as cell enter S-phase and decreasing again at the end of S-phase (Harris, 1991). Al together, these data could clarify why high HADMS score patients, distinguished by an active growth, can be efficiently targeted by the upregulation of HDACi/DNMTi targeted genes and especially the 54 with a good prognostic value.
• MMC of patients with a low HADMS score could be in a more quiescent stage.
• GSEA analysis revealed that MMC of patients with a low HADMS score showed a signature resembling mature BMPC associated with bone marrow microenvironment dependence underlined by a significant enrichment in intercellular communication signal pathways (Tables 5 to 9).
• MMC of patients with a high HADMS score are characterized by a signature sharing similarities with les differentiated proliferating plasmablastic progenitors (Tables 10 to 15).
• MMC progenitors including B cells and preplasmablasts were found to survive to proteasome inhibitors and to be significantly enriched in myeloma patients refractory to bortezomib treatment.
• Xbpls negative preblasmablastic cells are characterized by a diminished endoplasmic reticulum (ER) stress and thus resistance to proteasome inhibitors since they have not committed to high Ig production (Leung-Hagesteijn, 2013; Orlowski, 2013).
• plasmablastic progenitors have been described to overexpress epigenetic regulators, compared to mature plasma cells, suggesting that MMC transitions in plasma cell differentiation stages could be linked to epigenetic plasticity (Chaidos, 2013).
• HADMS score was significantly higher in preplasmablasts, plasmablasts and early plasma cells compared to normal mature BMPC ( Figure 5).
• HDACi/DNMTi combined treatment could have a therapeutic interest to target tumor progenitors that contribute to treatment failure in MM.
• Table 16 Genes communally overexpressed in decitabine and decitabine/TSA treated HMCLs
• Table 18 Genes communally overexpressed in TSA, decitabine and decitabine/TSA treated HMCLs
• Mitsiades CS Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. Jan 13 2004;101(2):540-545. 9. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. May 15 2003;101(10):4055-4062.
• NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. Oct 1 2003;102(7):2615-2622.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Medical Informatics (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Organic Chemistry (AREA)
• Data Mining & Analysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pathology (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• Databases & Information Systems (AREA)
• Primary Health Care (AREA)
• Wood Science & Technology (AREA)
• Molecular Biology (AREA)
• Zoology (AREA)
• Analytical Chemistry (AREA)
• Genetics & Genomics (AREA)
• Immunology (AREA)
• Artificial Intelligence (AREA)
• Computer Vision & Pattern Recognition (AREA)
• Bioethics (AREA)
• Evolutionary Computation (AREA)
• Software Systems (AREA)
• Theoretical Computer Science (AREA)
• Bioinformatics & Computational Biology (AREA)
• Spectroscopy & Molecular Physics (AREA)
• Evolutionary Biology (AREA)
• Biomedical Technology (AREA)
• General Engineering & Computer Science (AREA)
• Hospice & Palliative Care (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=50434142

Family Applications (1)

Country Status (4)

Cited By (1)

Families Citing this family (3)

Family Cites Families (1)

• 2015
  • 2015-03-20 EP EP15741765.0A patent/EP3119907B1/en active Active
  • 2015-03-20 JP JP2017500434A patent/JP6679561B2/ja active Active
  • 2015-03-20 WO PCT/EP2015/055992 patent/WO2015140321A1/en not_active Ceased
  • 2015-03-20 US US15/127,803 patent/US10662481B2/en active Active

Non-Patent Citations (75)

Also Published As

Similar Documents

Legal Events